Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents

Phase 1

Recruiting

• Conditions: Type1diabetes
• Interventions: Biological: the ATMP Protrans

• Registration Number: NCT05061030
• Lead Sponsor: Uppsala University Hospital

Brief Summary

This is a combined phase 1 and 2 study in 66 subjects, male or female, between 7-21 years of age that have recently (\< 6 months) been diagnosed with type 1 diabetes. The first phase 1 part of the study includes six subjects openly receiving allogeneic Wharton's jelly derived mesenchymal stromal cells as the Advanced Therapy Medicinal Product (ATMP) Protrans, three each in the age ranges 7-11 and 12-18.The second part is a randomized, double-blinded placebo-controlled phase 2 study in parallel design comparing allogeneic Wharton's jelly derived mesenchymal stromal cells treatment (as Protrans) to placebo in children and adolescent subjects (7-21 years of age) diagnosed with type 1 diabetes, The primary objectives of this study will be to investigate the safety, tolerance and efficacy after an allogieneic infusion of Wharton's jelly derived mesenchymal stromal cells.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-09-20
• Study First Submitted QC: 2021-09-20
• Study First Posted: 2021-09-29
• Study Start: 2022-01-14
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-04
• Last Update Posted: 2024-12-05
• Primary Completion: 2028-09
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

1. Written informed consent for participation of the study (for subjects below 18 years of age also from both caregivers), given before undergoing any study-specific procedures

2. Clinical history compatible with type 1 diabetes diagnosed less than 6 months before enrolment

3. In the first part of the study, six subjects, three between 7-11 and three between 12-18 years of age (both groups inclusive at both ends), will be included. The sixty subjects in the second part of the study are stratified by age (12-21 and 7-11 years, respectively) and randomized to one of two treatment arms (active or placebo), with a 6-month safety delay for the younger stratum.

4. Mentally stable and, in the opinion of the investigator, able to comply with the procedures of the study protocol.

5. Fasting plasma C-peptide concentration >0.12 nmol/L.

6. Subjects of child-bearing potential must agree to using adequate contraception until one year after the administration of WJMSC/Placebo. Adequate contraception is as follows:

   1. oral (except low-dose gestagen (lynestrenol and noretisteron), injectable or implanted hormonal contraceptives.
   2. intrauterine device
   3. intrauterine system (for example progestin-releasing coil)
   4. vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate)

Exclusion Criteria

1. Subjects with body weight >100 kg
2. Subjects with unstable cardiovascular status incl. NYHA class III/IV or symptoms of angina pectoris.
3. Subjects with uncontrolled hypertension (≥160/105 mmHg).
4. Subjects with active on-going infections.
5. Subjects with latent or previous as well as on-going therapy against tuberculosis, or exposed to tuberculosis or has traveled in areas with a high risk of tuberculosis or mycosis within the last 3 months.
6. Subjects with serological evidence of infection with HIV, Treponema pallidum, hepatitis B antigen (subjects with serology consistent with previous vaccination and a history of vaccination are acceptable), or hepatitis C.
7. Subjects with any systemic immune suppressive treatment
8. Subjects with a known demyelinating disease or with symptoms or physical examination findings consistent with possible demyelinating disease.
9. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
10. Subjects with known, or previous, malignancy.
11. Taking oral anti-diabetic therapies or any other concomitant medication which may interfere with glucose regulation other than insulin.
12. Subjects with GFR <60 ml/min/1.73 m2 body surface.
13. Subject with any condition or any circumstance that, in the opinion of the investigator, would make it unsafe to undergo treatment with MSC.
14. Known hypersensitivity against any excipients, i.e., dimethyl sulfoxide (DMSO).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Wharton's jelly derived mesenchymal stromal cells (Protrans)	the ATMP Protrans	Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects \< 50 kg and 200 million cells to subjects 50-100 kg (\>100 kg is an exclusion criterion).
Placebo	the ATMP Protrans	Placebo (saline) is given intravenously over a period of 20-40 min.

Primary Outcome Measures

Name	Time	Method
Safety at one year evaluated as adverse events	One year	Safety parameters will be evaluated at each study visit and recorded as adverse events.
Safety at five years evaluated as adverse events	Five years	Safety parameters will be evaluated at each study visit and recorded as adverse events.
Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.	One year	Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 12 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline).

Secondary Outcome Measures

Name	Time	Method
Insulin independency	One year	The proportion of study participants independent of insulin at 12 months
Time in target	12 months	Time in target (4-8 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months
Time in range	12 months	Time in target (3.9-10 mmol/l) as measured by flash glucose monitoring for 14 days at 12 months
C-peptide	6 months	Change in C-peptide Area under the curve (AUC) (0-120 min) for mixed meal tolerance test (MMTT) at 6 months following Protrans/Placebo infusion when compared to test performed before the start of treatment (baseline).
Low insulin needs	12 months	The proportion of study participants with daily insulin needs \<0.25 U/kg at 12 months
HbA1c	12 months	HbA1c at 12 months
Change in peak C-peptide	12 months	Change in peak C-peptide concentration during the first 12 months
Insulin needs	12 months	Insulin requirement/kg body weigh at 12 months

Trial Locations

Locations (1)

Uppsala University Hospital; 🇸🇪 Uppsala, Sweden